LAX.SH
CAPLIN POINT LAB LTD.·PHARMACEUTICALS 70.24·Pharmaceuticals & Biotechnology Companies
Price
2,560.8
+1.22%52W Range
Market Cap
₹19,465.08 Cr
Traded: ₹12.68 Cr (0.07%) 0.0x
Free Float: ₹3,566.00 Cr (0.36% of FF traded)
Volume · 60D trend
49.78 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | +25.0% | +23.0% | +22.0% | -- | -- | Decelerating |
| Return | +27.0% | +24.0% | +34.0% | +18.0% | -- | Stable |
| Profit | +30.0% | +22.0% | +20.0% | -- | +18.0% | Decelerating |
| Sales | +25.0% | +16.0% | +14.0% | -- | +15.0% | Stable |
Quarterly Results
Mar 2023
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 610 | 600 | 543 | 534 | 510 | 502 | 493 | 483 | 459 | 453 | 436 | 410 | 395 | 389 | 372 | 359 |
| Expenses | 397 | 396 | 353 | 345 | 332 | 334 | 331 | 318 | 307 | 308 | 293 | 273 | 269 | 265 | 263 | 253 |
| Operating Profit | 213 | 204 | 190 | 189 | 178 | 168 | 162 | 165 | 152 | 145 | 142 | 137 | 127 | 124 | 109 | 106 |
| OPM % | 35.0% | 34.0% | 35.0% | 35.0% | 35.0% | 33.0% | 33.0% | 34.0% | 33.0% | 32.0% | 33.0% | 34.0% | 32.0% | 32.0% | 29.0% | 29.0% |
| Other Income | 34 | 28 | 34 | 30 | 23 | 26 | 31 | 21 | 19 | 17 | 17 | 21 | 12 | 11 | 14 | 16 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 22 | 19 | 19 | 18 | 16 | 17 | 16 | 17 | 16 | 16 | 14 | 12 | 11 | 11 | 11 | 11 |
| Profit Before Tax | 225 | 213 | 204 | 201 | 184 | 177 | 177 | 168 | 154 | 146 | 145 | 146 | 127 | 124 | 112 | 110 |
| Tax % | 20.0% | 19.0% | 19.0% | 20.0% | 18.0% | 18.0% | 21.0% | 22.0% | 19.0% | 17.0% | 18.0% | 20.0% | 18.0% | 18.0% | 13.0% | 17.0% |
| Net Profit | 179 | 173 | 166 | 160 | 151 | 145 | 140 | 131 | 125 | 121 | 120 | 116 | 104 | 101 | 97 | 92 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 23.3 | 22.4 | 21.6 | 20.3 | 20.1 | 18.8 | 18.3 | 17.2 | 16.3 | 16.0 | 15.4 | 15.1 | 13.6 | 13.4 | 12.8 | 12.1 |
| Sales Growth (YoY) | 19.6% | 19.5% | 10.1% | 10.6% | 11.1% | 10.8% | 13.1% | 17.8% | 16.2% | 16.4% | 17.2% | 14.2% | -- | -- | -- | -- |
| Sales Growth (QoQ) | 1.7% | 10.5% | 1.7% | 4.7% | 1.6% | 1.8% | 2.1% | 5.2% | 1.3% | 3.9% | 6.3% | 3.8% | 1.5% | 4.6% | 3.6% | -- |
| OP Growth (YoY) | 19.7% | 21.4% | 17.3% | 14.5% | 17.1% | 15.9% | 14.1% | 20.4% | 19.7% | 16.9% | 30.3% | 29.2% | -- | -- | -- | -- |
| OP Growth (QoQ) | 4.4% | 7.4% | 0.5% | 6.2% | 6.0% | 3.7% | -1.8% | 8.6% | 4.8% | 2.1% | 3.6% | 7.9% | 2.4% | 13.8% | 2.8% | -- |
| Profit Growth (YoY) | -- | 19.0% | 18.0% | 18.0% | 23.0% | 17.0% | 19.0% | 14.0% | 20.0% | 19.0% | 20.0% | 25.0% | 22.0% | 29.0% | 30.0% | 22.0% |
| EPS Growth (YoY) | 15.8% | 19.3% | 17.9% | 18.1% | 23.2% | 17.2% | 18.5% | 13.8% | 19.8% | 19.0% | 20.2% | 25.1% | -- | -- | -- | -- |
| EPS Growth (QoQ) | 4.0% | 3.8% | 6.1% | 1.1% | 7.1% | 2.6% | 6.2% | 5.5% | 1.9% | 3.8% | 2.0% | 11.1% | 1.3% | 4.8% | 6.2% | -- |
| OP Margin | 34.9% | 34.0% | 35.0% | 35.4% | 34.9% | 33.5% | 32.9% | 34.2% | 33.1% | 32.0% | 32.6% | 33.4% | 32.1% | 31.9% | 29.3% | 29.5% |
| Net Margin | 29.3% | 28.8% | 30.6% | 30.0% | 29.6% | 28.9% | 28.4% | 27.1% | 27.2% | 26.7% | 27.5% | 28.3% | 26.3% | 26.0% | 26.1% | 25.6% |
| Material Cost % | -- | 40.8% | 39.6% | 39.4% | 38.3% | 40.0% | 39.6% | 39.1% | 40.4% | 43.4% | 43.6% | 40.0% | 44.7% | 45.4% | 44.0% | 46.1% |
| Employee Cost % | -- | 8.8% | 9.6% | 8.8% | 8.5% | 9.6% | 9.5% | 9.2% | 8.8% | 8.1% | 8.4% | 8.6% | 8.9% | 9.3% | 9.3% | 9.5% |
| P/S | 8.51 | 9.14 | 6.70 | 6.34 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 29.26 | 31.17 | 22.81 | 21.95 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 5.43 | 5.57 | 4.43 | 4.09 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Completion of Unannounced USFDA Inspection at the facility of Caplin Steriles Limited (Company''s subsidiary)
Transcript for Earnings call- Q1- FY 2026-27
Audio Recording of Earnings call for the Quarter ended June 30, 2026
Investor Presentation for the Earnings Call for the Quarter ended June 30, 2026.
The Board of Director in its meeting held today, August 12, 2026, approved the appointment of directors.
Financial Results for the quarter ended June 30, 2026
Record date for Final Dividend is September 18, 2026
Board meeting outcome for meeting held on August 12, 2026
Intimation pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018 for the quarter ended June 30, 2026
Intimation of closure of Trading Window commencing from July 01, 2026
Newspaper advertisement for transfer of Unclaimed dividend and shares to IEPF
Annual Secretarial Compliance report for the year ended March 31, 2026
Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Transcript for Earnings call- Q4- FY 2025-26
Earnings call for Q4(2025-26)
Press release regarding receipt of final approval by our subsidiary, Caplin Steriles Limited, from USFDA, for Foscarnet Sodium Injection
The Board at its meeting held today, May 14, 2026, had declared Interim Dividend of INR.4.00 (200%) per equity share for the FY 2025-26 and fixed the Record date as May 30, 2026.
Financial Results for the Quarter and Year ended March 31, 2026
The Board at its meeting held today, May 14, 2026, had 1. Approved the Audited standalone and consolidated financial results of the Company for the year ended March 31, 2026, along with ....
Q4 post-results conference call invite is enclosed herewith.
Caplin Point Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2026 ,inter alia, to consider and approve Audited financial ....
Press release regarding receipt of final approval by our Subsidiary, Caplin Steriles Limited, from USFDA for Calcium Gluconate Injection USP
Intimation pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026
Intimation of closure of Trading Window commencing from April 01, 2026
Press release regarding receipt of final approval by our subsidiary, Caplin Steriles Limited, from USFDA for the Potassium Phosphates Injection USP
Cessation of Dr. C K Gariyali as an Independent Director of the Company with effect from March 3, 2026.
Press Release regarding receipt of final approval by our Subsidiary, Caplin Steriles Limited, from USFDA for the Desmopressin Acetate Injection USP
Press release regarding receipt of final approval by our Subsidiary, Caplin Steriles Limited, from the USFDA for the Sodium Phosphates Injection USP
Transcript of the Earnings Call - Q3 - FY 2025-26
Outcome of the Board Meeting held on February 05, 2026
Unaudited standalone and Consolidated Financial Results for the Quarter and nine months ended December 31, 2025
Investor Presentation for the quarter and nine months ended December 31, 2025
Results - Analyst/Investor Meet - Earnings Call - Q3(2025-2026) - Audio Recording
Voting results and Scrutinizer report for the Postal Ballot dated January 31, 2026
Appointment of Directors of the Company
Analyst / investor Call for the quarter ended December 31, 2025
Caplin Point Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2026 ,inter alia, to consider and approve the unaudited Financial ....
Press Release regarding receipt of final approval by our Subsidiary, Caplin Steriles Limited, from the USFDA for the ANDA Methylprednisolone Acetate Injectable Suspension USP.
Intimation pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2025
Company had disseminated a press release containing information on acquisition of ten ANDAs from a Global generic manufacturing company.
We enclose herewith the Notice of Postal Ballot of Caplin Point Laboratories Limited seeking the approval of members for the resolutions mentioned in the Notice.
Intimation of Closure of Trading window commencing from January 01, 2026.
This is to inform you that INVIMA - Colombia conducted an inspection of the injectables facility of the Company located at Puducherry. The inspection was conducted between 8th December ....
Press Release on the company''s Subsidiary, Caplin Steriles Limited, getting USFDA approval for its ANDA Linezolid Injection 600 mg/ 300 mL (2 mg/mL) Single Dose Infusion Bags
Press Release regarding receipt of final approval by our Subsidiary, Caplin Steriles Limited from USFDA for ANDA Acetaminophen Injection, 1000 mg/100 mL (10 mg/ mL) single dose infusion bags.
Acquisition of land by Subsidiary at Mexico
Transcript of the Earnings Call - Q2 & H1 FY 2025-26
Results - Analyst/Investor Meet - Earnings Call - Q2(2025-2026) - Audio Recording
Outcome of the Board Meeting
Un-audited standalone and consolidated financial results for the quarter and half year ended 30th September 2025
Annual Reports
15Concalls
24Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025May 2025
31 May 2025Feb 2025
28 Feb 2025Nov 2024
30 Nov 2024Aug 2024
31 Aug 2024Aug 2024
31 Aug 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Nov 2023
30 Nov 2023Nov 2023
30 Nov 2023Aug 2023
31 Aug 2023May 2023
31 May 2023Feb 2023
28 Feb 2023Feb 2023
28 Feb 2023Nov 2022
30 Nov 2022May 2021
31 May 2021Feb 2021
28 Feb 2021Nov 2020
30 Nov 2020Aug 2020
31 Aug 2020Jun 2020
30 Jun 2020Oct 2019
31 Oct 2019Held by ETFs
17 ETFs hold CAPLIPOINT · sorted by weight
Held by Mutual Funds
23 schemes hold CAPLIPOINT · sorted by weight